Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women

Darling, G.; Johns, Jennifer; McCloud, Philip; Davis, Susan R.

doi:10.3109/13697139909038060

Cited by 16 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are compatible with the observation of a greater HT impact on TC and LDL-C on hyper-than in normo-lipidemic women 29 . We observed no modification in HDL-C levels, with LLA or HT (except for transdermal opposed estradiol, see below) which is in agreement with previous RCTs showing no modification 26,27 , or of low amplitude, either positive 25,27,30 , or negative 28 . Modulating effects may be less evident when HDL-C concentrations are already high (2/3 of women in our study had HDL-C higher than 1.55 mmol/l) or for women with lower clinical risk 30,31 .…”

Section: Impact Of Lla Treatment Or/and Ht On Ldl-c Level Risksupporting

confidence: 80%

“…When taken together, HT and LLA globally were not associated with major additional effects compared to LLA alone, as observed in small RCTs with hyperlipidemic women [24][25][26]28 . However, in women using EPT and LLA, we observed significant differences when comparing transdermal to oral estradiol, with higher HDL-C level for women also treated with fibrate, but lower TG and higher LDL-C levels, for those treated with statin.…”

Section: Impact Of Lla Treatment Or/and Ht On Ldl-c Level Riskmentioning

confidence: 64%

See 1 more Smart Citation

Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents

et al. 2008

View full text Add to dashboard Cite

Objective: To evaluate plasmatic lipid levels in elderly women in the general population as a function of use of lipid lowering agents (LLA) and hormone therapy (HT) Methods: 4271 women over 65 were recruited from three French cities. Analyses were performed after stratification by LLA treatment and HT and adjusting for a large range of socio-demographic and clinical factors.Results: Fifteen percent of women currently used HT (78% transdermal estradiol), and 30% were taking LLA. In this population, 4.6% of women were taking both HT and LLA (fibrate for 2.4% and statin for 2.2%). In non-LLA treated women, current HT was associated with lower total cholesterol, LDL-C, and non-HDL-C compared to never users. Women treated with LLA, also had lower total cholesterol, LDL-C, and non-HDL-C compared to non-LLA users, whereas triglyceride levels were the highest in statin users and lowest in fibrate users. Fibrate was associated with a more favorable lipid pattern than statin independently of HT use. In women without coronary heart disease or diabetes HT, statin, or fibrate

show abstract

Section: Impact Of Lla Treatment Or/and Ht On Ldl-c Level Risksupporting

confidence: 80%

Section: Impact Of Lla Treatment Or/and Ht On Ldl-c Level Riskmentioning

confidence: 64%

Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Hormone replacement therapy (HRT) is the effective regimen to prevent these diseases in postmenopausal women [5,6]; however, it is accompanied by an increased risk of unfavorable outcomes [7].…”

Section: Introductionmentioning

confidence: 99%

Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal Japanese women: a randomized placebo-controlled trial

et al. 2006

View full text Add to dashboard Cite

“…Serum bonespecific alkaline phosphatase (BSALP; Alkphase-B; Metra Biosystems, Mountain View, CA, USA) was measured by using a microplate coated with an anti-BSALP monoclonal antibody. Serum intact osteocalcin (OC) was measured by using a sandwich enzyme immunoassay (EIA) that uses polyclonal antibodies against 20 N-terminal residues (amino acids [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] and against 7 C-terminal residues (amino acids 43-49; Biomedical Technology, Stoughton, MA, USA). Urine samples were collected from a second voiding at the same time as blood collection, and they were stored at -20°C.…”

Section: Effects Of Isoflavone and Walking On Bone And Fat Massmentioning

confidence: 99%

“…(1)(2)(3)(4) Hormone replacement therapy (HRT) is an effective regimen that prevents these diseases in postmenopausal women. (5,6) However, the HRT trial carried out by the Women's Health Initiative (WHI) found that long-term use of HRT (follow-up, 5.2 years) poses serious risks and may increase the risk of heart attack and stroke. (7) Follow-up studies with the WHI will likely provide insight as to whether the increased risks and benefits of HRT therapy decline after the end of the therapy and the time at which this decline occurs as well as evaluation of the dose.…”

Section: Introductionmentioning

confidence: 99%

Effects of Isoflavone and Exercise on BMD and Fat Mass in Postmenopausal Japanese Women: A 1-Year Randomized Placebo-Controlled Trial

Oka

Tabata

et al. 2006

Journal of Bone and Mineral Research

121

116

View full text Add to dashboard Cite

The combined intervention of isoflavone intake and walking exercise over 1 year in postmenopausal Japanese women exhibited a trend for a greater effect on prevention of bone loss at the total hip and Ward's triangle regions. Introduction:The additive effects of isoflavones and exercise on bone and lipid metabolism have been shown in estrogen-deficient animals. In this study, we determined the effects of isoflavone intake, walking exercise, and their interaction on bone, fat mass, and lipid metabolism over 1 year in postmenopausal Japanese women. Materials and Methods: A total of 136 postmenopausal women at <5 years after the onset of menopause were randomly assigned to four groups: (1) placebo, (2) walking (45 minutes/day, 3 days/week) with placebo, (3) isoflavone intake (75 mg of isoflavone conjugates/day), and (4) combination of isoflavone plus walking. BMD, fat mass, serum lipid, and serum and urinary isoflavone concentrations were assessed. Results: A significant main effect of isoflavone on the reduction in trunk fat mass was obtained at 12 months. Significant main effects of walking on the reduction in fat mass in the whole body and the trunk were observed at 3, 6, and 12 months and that in the legs and arms at 6 and 12 months. Serum high-density lipoprotein (HDL)-cholesterol concentration significantly increased by 12 months after the walking and the combined intervention. After 12 months, a significant main effect of isoflavone on BMD was observed only at Ward's triangle. Walking prevented bone loss at the total hip and the Ward's triangle to significant degrees. The effect of the combined intervention on BMD at total hip and Ward's triangle regions was greater than that of either alone. No significant interaction was observed between isoflavone and walking in any measurements recorded during the study. Conclusions: Our study suggest that combined intervention of 75 mg/day of isoflavone intake and walking exercise 3 times/week for 1 year showed a trend for a greater effect on BMD at total hip and Ward's triangle regions than either alone. Intervention with isoflavone in postmenopausal Japanese women showed a modest effect on BMD compared with those in Westerners. Further studies over longer treatment duration that include assessment of BMD at various regions are necessary to ascertain the clinical significance of the combined intervention of isoflavone plus walking in postmenopausal women.

show abstract

Concurrent use of simvastatin and estrogen-progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women

Abstract: For postmenopausal women with hypercholesterolemia, use of a statin in combination with continuous combined oral estrogen and progestin therapy can result in a more cardioprotective lipoprotein-lipid profile than that achieved with either therapy used alone.

Cited by 16 publications

References 19 publications

Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents

Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents

Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal Japanese women: a randomized placebo-controlled trial

Effects of Isoflavone and Exercise on BMD and Fat Mass in Postmenopausal Japanese Women: A 1-Year Randomized Placebo-Controlled Trial

Contact Info

Product

Resources

About